

Freedom of Information Request	FOI 22-169	27 <sup>th</sup> April 2022
--------------------------------	------------	-----------------------------

**Q1. How many GP practices are in your Health Board/Health and Social Care Trust?**

72 GP practices

**Q2. For the financial years below how much did the Health Board spend on:**

**Osteoporosis medication with:**

**Oral bisphosphonates (alendronate, risedronate, ibandronate)**

**a. 2019/2020**

£2,263.17

**b. 2020/2021**

£1,975.11

**ii) Denosumab**

**a. 2019/2020 = £270,415.20**

**b. 2020/2021 = £52,536.80**

**b. DXA scans. Please provide:**

**i) budget/spend for DXA**

**a. 2019/2020 = £132,074**

**b. 2020/2021 = £141,360**

**ii) no. scans this provided**

**a. 2019/2020 = 3148**

**b. 2020/2021 = 2127**

**iii) n. DXA VFA (vertebral fracture assessment) scans commissioned**

**a. 2019/2020**

**b. 2020/2021**

This information is not held by the Health Board.

**Q3. What proportion of GP practices have a systematic process in place (e.g., regular data search) for identifying people who require a fracture risk assessment?**

This information is not held by the Health Board.

**Q4. What proportion of GP practices have osteoporosis identification/management tools embedded into their electronic patient management systems?**

**a) FRAX**

- b) **QFracture**
- c) **Other (please state)**

This information is not held by the Health Board.

**Q5. For financial years 2019/20 and 2021/22.**

- a) **What proportion of patients across your CCG aged 50 and over had a fracture risk assessment using FRAX or QFracture in line with NICE / NOGG recommendations?**

- i. **2019/2020**
- ii. **2020/2021**

- b) **What proportion of these were referred for a DXA scan?**

- i. **2019/2020**
- ii. **2020/2021**

This information is not held by the Health Board.

**Q6. What proportion of practices have an identified clinician or other healthcare professional with special interest in osteoporosis?**

This information is not held by the Health Board.

**Q7. What proportion of GP practices have access to a community pharmacist (CP)?**

**And: what proportion of these CPs have a designated role in identifying/managing osteoporosis? What proportion of these CPs routinely perform osteoporosis medication reviews?**

All GP practices have access in general terms to a community pharmacy. There are no services commissioned from community pharmacies for osteoporosis medication reviews.

**Q8. What proportion of GP practices have access to a First Contact Practitioner (FCP)?**

**What proportion of these FCPs have a designated role in identifying/managing OP?**

This information is not held by the Health Board.

**Q9. What proportion of patients being treated in primary care with osteoporosis medications have had a review of their medication within 12 months of treatment initiation?**

This information is not held by the Health Board.

**Q10. What proportion of patients being treated in primary care with oral bisphosphonate therapy have had their treatment reviewed at 5 years of treatment?**

This information is not held by the Health Board.